Basit öğe kaydını göster

dc.contributor.authorWilliams, Michael E.
dc.contributor.authorDrach, Johannes
dc.contributor.authorRamchandren, Radhakrishnan
dc.contributor.authorZhang, Lei
dc.contributor.authorCicero, Sherri
dc.contributor.authorFu, Tommy
dc.contributor.authorWitzig, Thomas E.
dc.contributor.authorBesisik, Sevgi
dc.contributor.authorGoy, Andre
dc.contributor.authorSinha, Rajni
dc.date.accessioned2021-03-05T09:00:14Z
dc.date.available2021-03-05T09:00:14Z
dc.date.issued2013
dc.identifier.citationGoy A., Sinha R., Williams M. E. , Besisik S., Drach J., Ramchandren R., Zhang L., Cicero S., Fu T., Witzig T. E. , "Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.", Journal of clinical oncology : official journal of the American Society of Clinical Oncology, cilt.31, ss.3688-95, 2013
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_9bc50fcf-61ab-4ed1-a4ff-bd8eba6f615e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/104713
dc.identifier.urihttps://doi.org/10.1200/jco.2013.49.2835
dc.description.abstractPurpose
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleSingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
dc.typeMakale
dc.relation.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
dc.contributor.departmentHackensack University Medical Center , ,
dc.identifier.volume31
dc.identifier.issue29
dc.identifier.startpage3688
dc.identifier.endpage95
dc.contributor.firstauthorID211375


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster